|
Orthologous residues
|
|
girdin (human): S1417‑p, girdin iso5 (human): S592‑p, girdin (mouse): S1417‑p, girdin (rat): S1397‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
Vero (epithelial) [girdin (human)]
|
|
Cellular systems studied:
cell lines
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
inhibition of upstream enzyme, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of constitutively active enzyme, siRNA inhibition of enzyme, transfection of dominant-negative enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
LY294002
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
wortmannin
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
PD98059
|
EGF
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, molecular association, regulation
|
|
Effect of modification (process):
cell motility, altered, cytoskeletal reorganization
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
ACTB (human)
|
|
Induces
|
|
cell motility, altered, cytoskeletal reorganization
|
microscopy-colocalization, yeast two-hybrid
|
|
